Insulin Resistance & Obesity — Blocks to Recognising Satiety | For Radiant Health

Insulin Resistance & Obesity —
Blocks to Recognising Satiety

Prevalence trajectories in the USA and United Kingdom, 1975–2022. Insulin resistance does not merely raise the risk of obesity — it directly blocks the neurological circuit that tells us we are full. Chronically elevated insulin raises triglyceride levels, which physically impair leptin transport across the blood-brain barrier; simultaneously, hypothalamic neurons develop leptin resistance at the receptor level. The satiety signal fails twice over. The person continues eating not through lack of willpower, but because the brain's "full" signal has been disrupted at its metabolic root. This is one of the most directly documented mechanistic connections in the entire insulin resistance series.

United States

USA — Insulin Resistance vs Obesity

1975 – 2022  |  % of adults
Insulin Resistance % (left axis)
Obesity % (right axis)
United Kingdom

UK — Insulin Resistance vs Obesity

1975 – 2022  |  % of adults
Insulin Resistance % (left axis)
Obesity % (right axis)
r = 0.97
USA
IR ↔ Obesity
r = 0.96
UK
IR ↔ Obesity
~40%
USA adults
obese (2022)
~29%
UK adults
obese (2022)

Why the two curves don't track each other exactly — even when the correlation is very high:

The solid line shows the percentage of adults with insulin resistance across the entire population — everyone with measurable insulin resistance, regardless of what condition it causes them. Because insulin resistance is the upstream root cause of many different diseases — type 2 diabetes, fatty liver, cognitive decline, cardiovascular disease and more — this curve rises relatively gradually as it reflects a burden shared across all of those outcomes.

The dotted line shows the prevalence of the specific condition studied on this page — in this case, only the people for whom insulin resistance has expressed itself as obesity. This curve rises steeply because it captures decades of accumulated cases: someone may develop insulin resistance at 35 but not cross the clinical obesity threshold (BMI ≥30) until their 40s or 50s, so even a modest early rise in insulin resistance translates into a much larger rise in diagnosed obesity years later.

The r value (e.g. r = 0.97) is a correlation coefficient. It doesn't measure whether the two lines are the same height — it measures how consistently they move together over time. An r of 0.97 means that 97% of the rise in obesity over the past five decades is statistically explained by the parallel rise in insulin resistance.

What the r value tells you:
0.50–0.70 — Modest connection. The two trends are related but other factors are involved.
0.70–0.90 — Strong connection. Insulin resistance is a major driver, alongside other contributing causes.
0.90 and above — Dominant connection. Insulin resistance accounts for the overwhelming majority of the trend. At this level, it is difficult to argue that other factors are primarily responsible. The values seen across these studies — consistently 0.90 to 0.97 — place insulin resistance firmly in this category for every condition shown.

The research: how insulin resistance blocks the ability to recognise satiety: Under normal metabolism, fat cells release leptin after eating, which travels to the hypothalamus and activates POMC neurons — the brain's satiety circuit — to produce the feeling of fullness and terminate eating. In insulin resistance, this circuit is blocked at two levels simultaneously.

First, a 2017 study in the International Journal of Obesity (Banks et al.) demonstrated experimentally that triglycerides — elevated chronically by insulin resistance — cross the blood-brain barrier and directly block the satiety effect of leptin at hypothalamic receptors. In their own words: "Central triolein blocked the satiety effect of centrally administered leptin." The more insulin-resistant the person, the higher their triglycerides, and the more completely the satiety signal is physically blocked from reaching the brain.

Second, at the cellular level, a 2017 study in Molecular Endocrinology (Taha et al., PMC5415275) showed that insulin resistance in hypothalamic neurons prevents leptin from activating its downstream signalling pathways (STAT3, Akt, ERK) — meaning even when leptin does reach the brain, the neurons can no longer respond to it. The satiety receptors are simultaneously blocked from the outside by triglycerides and desensitised from the inside by chronic insulin exposure.

The result: the brain never receives a clear "full" signal. The person continues eating not from lack of discipline but because the neurological circuit that registers fullness has been chemically disabled. Sources: Banks et al., Int J Obesity 2017 (doi:10.1038/ijo.2017.231); Taha et al., Mol Endocrinology 2017 (PMC5415275); Schwartz et al. Nature 2000; Friedman Lab Cell Metabolism 2025.
Is the effect worse in Type 2 diabetes? Yes — significantly. In Type 2 diabetes, both insulin resistance and leptin resistance are typically more entrenched. Triglyceride levels are higher, the blood-brain barrier is more compromised, and the hypothalamic leptin receptors have been chronically overstimulated. Additionally, ghrelin — the hunger hormone produced by the stomach — fails to drop after meals in T2DM patients as it would in healthy individuals, creating a second overeating signal that operates independently of leptin. The result is that people with Type 2 diabetes face a dual disruption of satiety: the "full" signal (leptin) is blocked, and the "still hungry" signal (ghrelin) remains inappropriately elevated. Studies estimate that leptin resistance co-exists with insulin resistance in approximately 75–80% of people with established Type 2 diabetes. Sources: Leptin and Ghrelin in T2DM — PMC11196531 (2024); Correlation of Leptin in T2DM — PMC11070180 (2024).
Data sources
Obesity USA — prevalence trend: NHANES historical series. Prevalence 15.0% in 1976–80 (NHANES II); 22.5% in 1988–94 (NHANES III); 30.9% in 1999–2000; 35.7% in 2011–12; 39.6% in 2015–16; 42.4% in 2017–18; 40.3% in 2021–23 (CDC NCHS Data Brief No.508, 2024). Pre-1976 estimates from NCD-RisC pooled global analysis (Lancet 2016). Five Decades of Change PMC10213181 (2023); Origins of the Obesity Epidemic PMC9611578 (2022).
https://www.cdc.gov/nchs/products/databriefs/db508.htm
https://pmc.ncbi.nlm.nih.gov/articles/PMC10213181/
Obesity UK — prevalence trend: Health Survey for England (HSE) series. 1980 National Heights and Weights Survey: 6% men / 9% women obese. HSE 1993: 13% men / 16% women. HSE 2000: ~21% combined. HSE 2010: ~26%. HSE 2019: 28% (UKHSA blog 2021). HSE 2022: 29% obese, 64% overweight or obese (NHS Digital 2024; Nuffield Trust; House of Commons Library 2025). Pre-1993 estimates from NCD-RisC Lancet 2016 pooled analysis.
https://digital.nhs.uk/data-and-information/publications/statistical/health-survey-for-england/2022-part-2/adult-overweight-and-obesity
https://commonslibrary.parliament.uk/research-briefings/sn03336/
https://ukhsa.blog.gov.uk/2021/03/04/patterns-and-trends-in-excess-weight-among-adults-in-england/
Satiety mechanism — IR causes leptin resistance and overeating: Münzberg H & Myers MG. Molecular and anatomical determinants of central leptin resistance. Nature Neuroscience 2005. Schwartz MW et al. Central nervous system control of food intake. Nature 2000. Obici S et al. Decreasing hypothalamic insulin receptors causes hyperphagia. Nature Neuroscience 2002. Tan B, Hedbacker K et al. mTOR hyperactivity in POMC neurons causes leptin resistance. Cell Metabolism 2025 (Rockefeller University). Wang J et al. Overfeeding rapidly induces leptin and insulin resistance. Diabetes 2001.
Leptin/ghrelin disruption in Type 2 diabetes: Leptin and Ghrelin Dynamics in T2DM. PMC 2024: https://pmc.ncbi.nlm.nih.gov/articles/PMC11196531/
Correlation of Leptin in T2DM. PMC 2024: https://pmc.ncbi.nlm.nih.gov/articles/PMC11070180/
Insulin Resistance USA & UK: NHANES III 1988–94; NHANES 1999–2018 (Hirode & Wong, JAMA 2020); NHS Health Survey England; GBD 2019 metabolic risk; Diabetes UK; Frontiers meta-analysis 2025.
https://pmc.ncbi.nlm.nih.gov/articles/PMC11601873/
https://www.diabetesuk.org/professionals/position-statements-reports/statistics/
All Conditions — Individual r Value Pages
ADHD  ·  Alzheimer's Disease  ·  Arthritis  ·  Asthma  ·  Hypertension  ·  IBS  ·  Multiple Sclerosis  ·  OCD  ·  Stroke  ·  Type 2 Diabetes
Many people with this condition have at least one other insulin-resistance-driven condition. See the full picture — all conditions, their r values, prevalence data, and 50-year rise figures in one place:  See all conditions →
Scroll to Top
MENU
For Radiant Health